Mauna Kea Technologies Announces the Availability of Preparatory Documents for the Combined General Meeting of June 6, 2024 and the Instructions for Participation
May 21 2024 - 11:45AM
Business Wire
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor
of Cellvizio®, the multidisciplinary probe and needle-based
confocal laser endomicroscopy (p/nCLE) platform, today announced
the availability of preparatory documents for the Combined General
Meeting of June 6, 2024, to be held at 11:00 a.m. at the Company's
head office at 9 rue d'Enghien, 75010 - Paris.
Notice of the meeting, including the agenda, proposed
resolutions and instructions for participating and voting at the
meeting were published in the Bulletin des Annonces Légales
Obligatoires (BALO) on May 1, 2024, bulletin n°53, announcement
2400984.
This notice of meeting, together with the documents and
information relating to the Combined General Meeting and the single
voting form, can be accessed via the Company's website in the
"Investors" section of the Shareholders' Meeting area, at the
following address
https://www.maunakeatech.com/fr/investisseurs/assemblee-generale.
Any shareholder may also obtain the documents referred to above,
in accordance with Articles R.225-88 and R.225-89 of the French
Commercial Code, by sending a written request to the Company's
registered office at 9 rue d'Enghien, 75010 Paris. However, the
Company invites shareholders to send all requests electronically to
the following address ag@maunakeatech.com.
Voting procedures
The Company's shareholders are invited to exercise their voting
rights prior to the Annual General Meeting in accordance with the
procedures set out below and detailed in the notice of meeting
brochure published today on the Company's website:
- Voting by mail or by proxy (by
giving power of attorney to the Chairman of the Meeting or to a
third party, or without specifying a proxy) by VOTACCESS
electronic means is available and should be used as a priority.
The secure VOTACCESS platform will be open from Friday May 17, 2024
at 9 a.m. (Paris time) and will close on Wednesday June 5, 2024 at
3 p.m. (Paris time). However, shareholders are strongly advised not
to wait until the last few days to enter their voting instructions;
- Postal voting or proxy voting; - Shareholders may also
attend the Meeting in person.
Besides, shareholders may submit written questions to the
following e-mail address ag@maunakeatech.com prior to the Annual
General Meeting, until midnight on Friday, May 31, 2024, providing
proof of shareholder status.
About Mauna Kea Technologies Mauna Kea Technologies is a
global medical device company that manufactures and sells
Cellvizio®, the real-time in vivo cellular imaging platform. This
technology uniquely delivers in vivo cellular visualization which
enables physicians to monitor the progression of disease over time,
assess point-in-time reactions as they happen in real time,
classify indeterminate areas of concern, and guide surgical
interventions. The Cellvizio® platform is used globally across a
wide range of medical specialties and is making a transformative
change in the way physicians diagnose and treat patients. For more
information, visit www.maunakeatech.com.
Disclaimer This press release contains forward-looking
statements about Mauna Kea Technologies and its business. All
statements other than statements of historical fact included in
this press release, including, but not limited to, statements
regarding Mauna Kea Technologies' financial condition, business,
strategies, plans and objectives for future operations are
forward-looking statements. Mauna Kea Technologies believes that
these forward-looking statements are based on reasonable
assumptions. However, no assurance can be given that the
expectations expressed in these forward-looking statements will be
achieved. These forward-looking statements are subject to numerous
risks and uncertainties, including those described in Chapter 2 of
Mauna Kea Technologies' 2023 Annual Report filed with the Autorité
des marchés financiers (AMF) on April 30, 2024, which is available
on the Company's website (www.maunakeatech.fr), as well as the
risks associated with changes in economic conditions, financial
markets and the markets in which Mauna Kea Technologies operates.
The forward-looking statements contained in this press release are
also subject to risks that are unknown to Mauna Kea Technologies or
that Mauna Kea Technologies does not currently consider material.
The occurrence of some or all of these risks could cause the actual
results, financial condition, performance or achievements of Mauna
Kea Technologies to differ materially from those expressed in the
forward-looking statements. This press release and the information
contained herein do not constitute an offer to sell or subscribe
for, or the solicitation of an order to buy or subscribe for,
shares of Mauna Kea Technologies in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such
jurisdiction. The distribution of this press release may be
restricted in certain jurisdictions by local law. Persons into
whose possession this document comes are required to comply with
all local regulations applicable to this document.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240521898490/en/
Mauna Kea Technologies
investors@maunakeatech.com
NewCap - Investor Relations
Aurélie Manavarere / Thomas Grojean +33 (0)1 44 71 94 94
maunakea@newcap.eu
Mauna Kea Technologies (EU:ALMKT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mauna Kea Technologies (EU:ALMKT)
Historical Stock Chart
From Jul 2023 to Jul 2024